ClinicalTrials.govpublic full text
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
renal cancer, melanoma, unresectable, metastatic, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 836524
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.